慢性阻塞性肺疾病肺动脉高压的生物标志物及其意义
|
摘要
<正>慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)是一种以持续气流受限为特征的可以预防和治疗的疾病,它是呼吸系统疾病中的常见病和多发病,患病率和病死率均居高不下,严重影响患者的生存质量和劳动能力~([1])。全球疾病负担研究估计,2015年全球有17 450万成年人患有COPD~([2]),如果包含肺功能测定的COPD,疾病负担可能高达3.84亿美元~([3])。估计在2015年全球有200万人死于C
Chronic obstructive pulmonary disease(COPD)is a lung disease with airflow limitation.The incidence and mortality are high,which seriously affects the patient's quality of life and labor ability.Pulmonary arterial hypertension(PAH)is a frequent complication of COPD,which is one of the main causes of death in COPD patient.Therefore,some standard,noninvasive and objective biomarkers are needed in clinic,which are meaningful for early diagnosis,severity assessment,therapeutic method selection,therapeutic effect evaluation and prognosis judgment of PAH.The present article made a review about research on biomarkers related to PAH.
Chronic obstructive pulmonary disease(COPD)is a lung disease with airflow limitation.The incidence and mortality are high,which seriously affects the patient's quality of life and labor ability.Pulmonary arterial hypertension(PAH)is a frequent complication of COPD,which is one of the main causes of death in COPD patient.Therefore,some standard,noninvasive and objective biomarkers are needed in clinic,which are meaningful for early diagnosis,severity assessment,therapeutic method selection,therapeutic effect evaluation and prognosis judgment of PAH.The present article made a review about research on biomarkers related to PAH.
引文
[1] GBD 2015 Disease and Injury Incidence and Prevalence Collaborators.Global,regional,and national incidence,prevalence,and years lived with disability for 310 diseases and injuries,1990-2015:a systematic analysis for the Global Burden of Disease Study 2015[J].Lancet,2016,388(10053):1545-1602.
[2] GBD 2015 Chronic Respiratory Disease Collaborators.Global,regional,and national deaths,prevalence,disability-adjusted life years,and years lived with disability for chronic obstructive pulmonary disease and asthma,1990-2015:a systematic analysis for the Global Burden of Disease Study 2015[J].Lancet Respir Med,2017,5(9):691-706.
[3] Adeloye D,Chua S,Lee C,et al.Global and regional estimates of COPD prevalence:systematic review and meta-analysis[J].J Glob Health,2015,5(2):020415.
[4] GBD 2015 Mortality and Causes of Death Collaborators.Global,regional,and national life expectancy,all-cause mortality,and cause-specific mortality for 249 causes of death,1980-2015:a systematic analysis for the Global Burden of Disease Study 2015[J].Lancet,2016,388(10053):1459-1544.
[5] Wang C,Xu JY,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH]study):A national cross-sectional study[J].Lancet,2018,391(10131):1706-1717.
[6] Zeng M,Li Y,Jiang YJ,et al.Local and systemic oxidative stress and glucocorticoid receptor levels in chronic obstructive pulmonary disease patients[J].Can Respir J,2013,20(1):35-41.
[7] Subias PE.Comments on the 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J].Rev Esp Cardiol(Engl Ed),2016,69(2):102-108.
[8] Chen X,Tang S,Liu K,et al.Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension:a systematic review and meta-analysis[J].J Thorac Dis,2015,7(3):309-319.
[9] Rosenkranz S,Gibbs JS,Wachter R,et al.Left ventricu1ar heart failure and pulmonary hypertension[J].Eur Heart J,2016,37(12):942-954.
[10] Held M,Linke M,Jany B,et al.Echocardiography and right heart catheterization in pulmonary hypertension[J].Dtsch Med Wochenschr,2014,139(30):1511-1517.
[11] Solidoro P,Patrucco F,Bonato R,et al.Pulmonary hypertension in chronic obstructive pulmonary disease and pulmonary fibrosis:prevalence and hemodynamic differences in lung transplant recipients at transplant center’s referral time[J].Transplantation Proceedings,2015,47(7):2161-2165.
[12] Brozaitiene J,Mickuviene N,Podlipskyte A,et al.Relationship and prognostic importance of thyroid hormone and N-terminal pro-B-Type natriuretic peptide for patients after acute coronary syndromes:A longitudinal observational study[J].BMC Cardiovasc Disord,2016,16(1):45.
[13] Psotka MA,Schiller NB,Whooley MA,et al.Association of change in 5-year N-terminal fragment of the prohormone brain-type natriuretic peptide with left ventricular structure and function in stable coronary disease[J].J Cardiovasc Med(Hagerstown),2018,19(2):67-72.
[14] Kraen M,Frantz S,Nihlén U,et al.Brain natriuretic peptide levels in middle aged subjects with normal left ventricular function in relation to mild-moderate COPD[J].Clin Respir J,2018,12(4):1061-1067.
[15] Agoston-Coldea L,Petrovai D,Mihalcea I,et al.Right atrium volume index in patients with secondary pulmonary hypertension due to chronic obstructive pulmonary disease[J].Acta Cardiol Sin,2015,31(4):325-336.
[16] Volpe M,Carnovali M,Mastromarino V.The natriuretic peptides system in the pathophysiology of heart failure:from molecular basis to treatment[J].Clinical Science,2016,130(2):57-77.
[17] Calvier L,Legchenko E,Grimm L,et al.Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension[J].Heart,2016,102(5):390-396.
[18] Chen Y,Liu C,Lu W,et al.Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases:a retrospective study[J].J Thorac Dis,2016,8(3):350-358.
[19] Ozdemirel TS,Ula?li SS,Yeti? B,et al.Effects of right ventricular dysfunction on exercise capacity and quality of life and associations with serum NT-proBNP levels in COPD:an observational study[J].Anadolu Kardiyol Derg,2014,14(4):370-377.
[20] Ma DF,Wang YC,Jiang P,et al.N-terminal pro-B-type natriuretic peptide levels inversely correlated with heart rate variability in patients with unstable angina pectoris[J].Int Heart J,2016,57(3):292-298.
[21] Lau EM,Tamura Y,McGoon MD,et al.The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:a practical chronicle of progress[J].Eur Respir J,2015,46(4):879-882.
[22] Ju CR,Chen M,Zhang JH,et al.Higher plasma myostatin levels in cor pulmonale secondary to chronic obstructive pulmonary disease[J].PLoS One,2016,11(3):e0150838.
[23] 王同生,苏秀丽,孙瑜霞,等.肌肉生长抑制蛋白对慢性阻塞性肺疾病合并肺动脉高压患者的预测意义[J].中华结核和呼吸杂志,2017,40(7):533-535.
[24] Springer J,Springer JI,Anker SD.Muscle wasting and sarcopenia in heart failure and beyond:update 2017[J].ESC Heart Failure,2017,4(4):492-498.
[25] Ju CR,Zhang JH,Chen M,et al.Plasma myostatin levels are related to the extent of right ventricular dysfunction in exacerbation of chronic obstructive pulmonary disease[J].Biomarkers,2017,22(3-4):246-252.
[26] Spiljar M,Merkler D,Trajkovski M.The immune system bridges the gut microbiota with systemic energy homeostasis:focus on tlrs,mucosal barrier,and SCFAs[J].Front Immunol,2017,8:1353.
[27] Rahimi-Rad MH,Rahimi P,Rahimi B,et al.Serum CA-125 level in patients with chronic obstructive pulmonary disease with and without pulmonary hypertension[J].Pneumologia,2014,63(3):164.
[28] 张明,李雅莉,杨侠,等.血清糖类抗原125在慢性阻塞性肺疾病急性加重期中的临床意义[J].南方医科大学学报,2016,36(10):1386-1389,1400.
[29] Krintus M,Kozinski M,Kubica J,et al.Critical appraisal of inflammatory markers in cardiovascular risk stratification[J].Crit Rev Clin Lab Sci,2014,51(5):263-279.
[30] Ghobadi H,Fouladi N,Beukaghazadeh K,et al.Association of high sensitive CRP level and COPD Assessment test scores with clinically important predictive outcomes in stable copd patients[J].Tanaffos,2015,14(1):34-41.
[31] Varga J,Palinkas A,Lajko I,et al.Pulmonary arterial pressure response during exercise in COPD:A correlation with C-reactive protein(hsCRP)[J].Open Respir Med J,2016,10:1-11.
[32] Ansarin K,Rashidi F,Namdar H,et al.Echocardiographic Evaluation of the Relationship Between inflammatory factors(IL6,TNFα,hs-CRP)and Secondary Pulmonary Hypertension in patients with COPD.A Cross sectional study[J].Pneumologia,2015,64(3):31-35.
[33] Tertemiz KC,Ozgen Alpaydin A,Sevinc C,et al.Could“red cell distribution width”predict COPD severity?[J].Rev Port Pneumol(2006),2016,22(4):196-201.
[34] Wang W,Liu J,Yang YH,et al.Red cell distribution width is increased in chronic thromboembolic pulmonary hypertension[J].Clin Respir J,2016,10(1):54-60.
[35] Xi QY,Liu ZH,Zhao ZH,et al.Red blood cell distribution width predicts responsiveness of acute pulmonary vasodilator testing in patients with idiopathic pulmonary arterial hypertension[J].Clin Chim Acta,2015,446:272-276.
[36] Polverino F,Celli BR,Owen CA.COPD as an endothelial disorder:endothelial injury linking lesions in the lungs and other organs?(2017 Grover Conference Series)[J].Pulm Circ,2018,8(1):204589401875852.
[37] Lacedonia D,Valerio G,Palladino GP,et al.Role of vasoactive intestinal peptide in chronic obstructive pulmonary disease with pulmonary hypertension[J].Rejuvenation Res,2014,17(1):33-39.
[38] Moy ML,Teylan M,Weston NA,et al.Daily step count is associated with plasma C-reactive protein and IL-6 in a US cohort with COPD[J].Chest,2014,145(3):542-550.
[39] Maston LD,Jones DT,Giermakowska W,et al.Interleukin-6 trans-signaling contributes to chronic hypoxia-induced pulmonary hypertension[J].Pulm Circ,2018,8(3):204589401878073.
[40] Lacedonia D,Valerio G,Palladino GP,et al.Role of vasoactive intestinal peptide in chronic obstructive pulmonary disease with pulmonary hypertension[J].Rejuvenation Res,2014,17(1):33-39.
[41] Lüneburg N,Harbaum L,Hennigs JK.The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases[J].Biomed Res Int,2014,2014:501612.
[42] Cordina R,Grieve S,Barnett M,et al.Brain volumetrics,regional cortical thickness and radiographic findings in adults with cyanotic congenital heart disease[J].NeuroImage:Clinical,2014,4(1):319-325.
[43] Telo S,K?rk?l G,Kulu?ztürk M,et al.Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive pulmonary disease?[J].Clin Respir J,2018,12(4):1433-1438.
[44] Parmaks?z ET,Inal A,Salepci B,et al.Relationship of asymmetric dimethylarginine levels with disease severity and pulmonary hypertension in chronic obstructive pulmonary disease[J]Lung India,2018,35(3):199-203.
[45] Marra AM,Benjamin N,Eichstaedt C,et al.Gender-related differences in pulmonary arterial hypertension targeted drugs administration[J].Pharmacol Res,2016,14:103-109.
[2] GBD 2015 Chronic Respiratory Disease Collaborators.Global,regional,and national deaths,prevalence,disability-adjusted life years,and years lived with disability for chronic obstructive pulmonary disease and asthma,1990-2015:a systematic analysis for the Global Burden of Disease Study 2015[J].Lancet Respir Med,2017,5(9):691-706.
[3] Adeloye D,Chua S,Lee C,et al.Global and regional estimates of COPD prevalence:systematic review and meta-analysis[J].J Glob Health,2015,5(2):020415.
[4] GBD 2015 Mortality and Causes of Death Collaborators.Global,regional,and national life expectancy,all-cause mortality,and cause-specific mortality for 249 causes of death,1980-2015:a systematic analysis for the Global Burden of Disease Study 2015[J].Lancet,2016,388(10053):1459-1544.
[5] Wang C,Xu JY,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH]study):A national cross-sectional study[J].Lancet,2018,391(10131):1706-1717.
[6] Zeng M,Li Y,Jiang YJ,et al.Local and systemic oxidative stress and glucocorticoid receptor levels in chronic obstructive pulmonary disease patients[J].Can Respir J,2013,20(1):35-41.
[7] Subias PE.Comments on the 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J].Rev Esp Cardiol(Engl Ed),2016,69(2):102-108.
[8] Chen X,Tang S,Liu K,et al.Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension:a systematic review and meta-analysis[J].J Thorac Dis,2015,7(3):309-319.
[9] Rosenkranz S,Gibbs JS,Wachter R,et al.Left ventricu1ar heart failure and pulmonary hypertension[J].Eur Heart J,2016,37(12):942-954.
[10] Held M,Linke M,Jany B,et al.Echocardiography and right heart catheterization in pulmonary hypertension[J].Dtsch Med Wochenschr,2014,139(30):1511-1517.
[11] Solidoro P,Patrucco F,Bonato R,et al.Pulmonary hypertension in chronic obstructive pulmonary disease and pulmonary fibrosis:prevalence and hemodynamic differences in lung transplant recipients at transplant center’s referral time[J].Transplantation Proceedings,2015,47(7):2161-2165.
[12] Brozaitiene J,Mickuviene N,Podlipskyte A,et al.Relationship and prognostic importance of thyroid hormone and N-terminal pro-B-Type natriuretic peptide for patients after acute coronary syndromes:A longitudinal observational study[J].BMC Cardiovasc Disord,2016,16(1):45.
[13] Psotka MA,Schiller NB,Whooley MA,et al.Association of change in 5-year N-terminal fragment of the prohormone brain-type natriuretic peptide with left ventricular structure and function in stable coronary disease[J].J Cardiovasc Med(Hagerstown),2018,19(2):67-72.
[14] Kraen M,Frantz S,Nihlén U,et al.Brain natriuretic peptide levels in middle aged subjects with normal left ventricular function in relation to mild-moderate COPD[J].Clin Respir J,2018,12(4):1061-1067.
[15] Agoston-Coldea L,Petrovai D,Mihalcea I,et al.Right atrium volume index in patients with secondary pulmonary hypertension due to chronic obstructive pulmonary disease[J].Acta Cardiol Sin,2015,31(4):325-336.
[16] Volpe M,Carnovali M,Mastromarino V.The natriuretic peptides system in the pathophysiology of heart failure:from molecular basis to treatment[J].Clinical Science,2016,130(2):57-77.
[17] Calvier L,Legchenko E,Grimm L,et al.Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension[J].Heart,2016,102(5):390-396.
[18] Chen Y,Liu C,Lu W,et al.Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases:a retrospective study[J].J Thorac Dis,2016,8(3):350-358.
[19] Ozdemirel TS,Ula?li SS,Yeti? B,et al.Effects of right ventricular dysfunction on exercise capacity and quality of life and associations with serum NT-proBNP levels in COPD:an observational study[J].Anadolu Kardiyol Derg,2014,14(4):370-377.
[20] Ma DF,Wang YC,Jiang P,et al.N-terminal pro-B-type natriuretic peptide levels inversely correlated with heart rate variability in patients with unstable angina pectoris[J].Int Heart J,2016,57(3):292-298.
[21] Lau EM,Tamura Y,McGoon MD,et al.The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:a practical chronicle of progress[J].Eur Respir J,2015,46(4):879-882.
[22] Ju CR,Chen M,Zhang JH,et al.Higher plasma myostatin levels in cor pulmonale secondary to chronic obstructive pulmonary disease[J].PLoS One,2016,11(3):e0150838.
[23] 王同生,苏秀丽,孙瑜霞,等.肌肉生长抑制蛋白对慢性阻塞性肺疾病合并肺动脉高压患者的预测意义[J].中华结核和呼吸杂志,2017,40(7):533-535.
[24] Springer J,Springer JI,Anker SD.Muscle wasting and sarcopenia in heart failure and beyond:update 2017[J].ESC Heart Failure,2017,4(4):492-498.
[25] Ju CR,Zhang JH,Chen M,et al.Plasma myostatin levels are related to the extent of right ventricular dysfunction in exacerbation of chronic obstructive pulmonary disease[J].Biomarkers,2017,22(3-4):246-252.
[26] Spiljar M,Merkler D,Trajkovski M.The immune system bridges the gut microbiota with systemic energy homeostasis:focus on tlrs,mucosal barrier,and SCFAs[J].Front Immunol,2017,8:1353.
[27] Rahimi-Rad MH,Rahimi P,Rahimi B,et al.Serum CA-125 level in patients with chronic obstructive pulmonary disease with and without pulmonary hypertension[J].Pneumologia,2014,63(3):164.
[28] 张明,李雅莉,杨侠,等.血清糖类抗原125在慢性阻塞性肺疾病急性加重期中的临床意义[J].南方医科大学学报,2016,36(10):1386-1389,1400.
[29] Krintus M,Kozinski M,Kubica J,et al.Critical appraisal of inflammatory markers in cardiovascular risk stratification[J].Crit Rev Clin Lab Sci,2014,51(5):263-279.
[30] Ghobadi H,Fouladi N,Beukaghazadeh K,et al.Association of high sensitive CRP level and COPD Assessment test scores with clinically important predictive outcomes in stable copd patients[J].Tanaffos,2015,14(1):34-41.
[31] Varga J,Palinkas A,Lajko I,et al.Pulmonary arterial pressure response during exercise in COPD:A correlation with C-reactive protein(hsCRP)[J].Open Respir Med J,2016,10:1-11.
[32] Ansarin K,Rashidi F,Namdar H,et al.Echocardiographic Evaluation of the Relationship Between inflammatory factors(IL6,TNFα,hs-CRP)and Secondary Pulmonary Hypertension in patients with COPD.A Cross sectional study[J].Pneumologia,2015,64(3):31-35.
[33] Tertemiz KC,Ozgen Alpaydin A,Sevinc C,et al.Could“red cell distribution width”predict COPD severity?[J].Rev Port Pneumol(2006),2016,22(4):196-201.
[34] Wang W,Liu J,Yang YH,et al.Red cell distribution width is increased in chronic thromboembolic pulmonary hypertension[J].Clin Respir J,2016,10(1):54-60.
[35] Xi QY,Liu ZH,Zhao ZH,et al.Red blood cell distribution width predicts responsiveness of acute pulmonary vasodilator testing in patients with idiopathic pulmonary arterial hypertension[J].Clin Chim Acta,2015,446:272-276.
[36] Polverino F,Celli BR,Owen CA.COPD as an endothelial disorder:endothelial injury linking lesions in the lungs and other organs?(2017 Grover Conference Series)[J].Pulm Circ,2018,8(1):204589401875852.
[37] Lacedonia D,Valerio G,Palladino GP,et al.Role of vasoactive intestinal peptide in chronic obstructive pulmonary disease with pulmonary hypertension[J].Rejuvenation Res,2014,17(1):33-39.
[38] Moy ML,Teylan M,Weston NA,et al.Daily step count is associated with plasma C-reactive protein and IL-6 in a US cohort with COPD[J].Chest,2014,145(3):542-550.
[39] Maston LD,Jones DT,Giermakowska W,et al.Interleukin-6 trans-signaling contributes to chronic hypoxia-induced pulmonary hypertension[J].Pulm Circ,2018,8(3):204589401878073.
[40] Lacedonia D,Valerio G,Palladino GP,et al.Role of vasoactive intestinal peptide in chronic obstructive pulmonary disease with pulmonary hypertension[J].Rejuvenation Res,2014,17(1):33-39.
[41] Lüneburg N,Harbaum L,Hennigs JK.The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases[J].Biomed Res Int,2014,2014:501612.
[42] Cordina R,Grieve S,Barnett M,et al.Brain volumetrics,regional cortical thickness and radiographic findings in adults with cyanotic congenital heart disease[J].NeuroImage:Clinical,2014,4(1):319-325.
[43] Telo S,K?rk?l G,Kulu?ztürk M,et al.Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive pulmonary disease?[J].Clin Respir J,2018,12(4):1433-1438.
[44] Parmaks?z ET,Inal A,Salepci B,et al.Relationship of asymmetric dimethylarginine levels with disease severity and pulmonary hypertension in chronic obstructive pulmonary disease[J]Lung India,2018,35(3):199-203.
[45] Marra AM,Benjamin N,Eichstaedt C,et al.Gender-related differences in pulmonary arterial hypertension targeted drugs administration[J].Pharmacol Res,2016,14:103-109.